<DOC>
	<DOCNO>NCT01169818</DOCNO>
	<brief_summary>Primary Objective : To compare patient-led titration ( intervention group ) versus physician-led titration ( usual standard care ) optimize clinical use insulin glargine Asian population patient Type 2 diabetes mellitus ( T2DM ) uncontrolled oral antidiabetic drug ( OADs ) . Secondary Objectives : To determine difference glycemic control , safety , quality life treatment satisfaction patient-led titration usual care .</brief_summary>
	<brief_title>Evaluation Effectiveness Safety Physician Versus Patient-led Insulin Glargine Initiation Titration Type 2 Diabetes Mellitus</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin Glargine</mesh_term>
	<criteria>Inclusion criterion : 1 . Diagnosed T2DM duration T2DM &gt; 2 year 2 . Insulin na√Øve 3 . Continuous treatment stable dose 2 OADs ( sulphonylureas , biguanides , alphaglucosidase inhibitor , DPPIV inhibitor , glinides ) &gt; three month prior randomization 4 . HbA1c level 7 % 11 % 5 . Body mass index ( BMI ) 20 40 kg/m2 6 . Willing able perform blood glucose monitoring use blood glucose meter Exclusion criterion : 1 . Diabetes type 2 diabetes ( e.g . secondary pancreatic disorder , drug chemical agent intake ) , 2 . Current previous use insulin ( except previous treatment gestational diabetes brief treatment insulin &lt; 1 week ) , 3 . Current treatment thiazolidinediones , 4 . Current previous use ( within last 3 month ) GLP1 receptor agonist GLP1 analogue , 5 . Current previous ( within last 3 month ) use treatment weight lose , 6 . Active proliferative diabetic retinopathy , 7 . Patient without history eye examination past 6 month , 8 . Treatment systemic corticosteroid 3 month prior study entry , 9 . Currently receive treatment monoamine oxidase inhibitor , 10 . Currently receive treatment nonselective blocker , 11 . Treatment investigational product and/or device 2 month prior study entry , 12 . Likelihood require treatment study period drug permit clinical trial protocol , 13 . History ketoacidosis hyperosmolar hyperglycemic state , 14 . History stroke , myocardial infarction , angina pectoris , coronary artery bypass graft percutaneous transluminal coronary angioplasty within previous 12 month , 15 . History congestive heart failure , 16 . History hypoglycemia unawareness , 17 . Unexplained hypoglycemia past 6 month , 18 . Impaired renal function define , limited , serum creatinine 1.5 mg/dL ( 133 mol/L ) males 1.4 mg/dL ( 124 mol/L ) females presence macroproteinuria ( &gt; 2gr/day ) , 19 . Active liver disease ( alanine transaminase ALAT great two time upper limit reference range , define local laboratory ) , 20 . Have condition ( include know substance alcohol abuse psychiatric disorder ) preclude patient follow complete study protocol , 21 . Had blood transfusion severe blood loss within 3 month screen , know hemoglobinopathy , hemolytic anemia sickle cell anemia , 22 . Known hypersensitivity / intolerance insulin glargine excipients , 23 . History pancreatitis , 24 . Currently undergo therapy plan radiological examination require administration contrast agent malignancy ( nonmetastatic / early stage basal cell squamous cell carcinoma ) , 25 . Pregnant lactate woman ( woman childbearing potential must negative pregnancy test study entry medically approve contraception method ) , 26 . Any medical condition may influence HbA1c rate . The information intend contain consideration relevant patient 's potential participation clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>July 2013</verification_date>
</DOC>